CRISPR gene therapy Casgevy can nearly eliminate sickle cell crises, but difficult stem‑cell collection is delaying access ...

The bus is designed to expand access to lifesaving, next-generation treatments across nearly 70,000 square miles of underserved communities in South Texas.

・Phase 2 data showed rapid increases in CD34+ stem cells, allowing same-day dosing and collection. ・Daratumumab-treated patients, who often struggle with mobilization, also achieved strong collection ...

- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...

The MarketWatch News Department was not involved in the creation of this content. BOCA RATON, Fla., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Gift of Life Marrow Registry marked a major milestone with a ...

The UK's first stem cell collection centre strictly dedicated to transplants has started welcoming donors. The Anthony Nolan Cell Collection Centre, based at Nottingham's Queen's Medical Centre (QMC), ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into ...

The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma. Stem cell transplantation is an important treatment method for ...

All cell types found in the body are derived from stem cells. However, genetic mutations can impact the ability of stem cells to develop into fully functional cells. Also, as the body ages, the number ...

The US Food and Drug Administration (FDA) has approved motixafortide (Aphexda, BioLineRx) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells for collection and subsequent ...

Dose-intensive cyclophosphamide, etoposide, cisplatin reinduction for relapsed/refractory aggressive non-Hodgkin lymphoma (r/r-aNHL). The comparison of up-front autologous peripheral stem cell ...